T1	Measurement 4 32	difference in blood pressure
T2	Qualifier 45 81	selected arm versus non-selected arm
R1	Has_qualifier Arg1:T1 Arg2:T2	
T3	Value 85 94	= 20 mmHg
T4	Value 109 118	= 10 mmHg
T5	Measurement 123 128	siDBP
T6	Measurement 99 104	siSBP
R2	Has_value Arg1:T6 Arg2:T3	
R3	Has_value Arg1:T5 Arg2:T4	
T7	Temporal 129 139	at Visit 1
R4	AND Arg1:T1 Arg2:T6	
R5	AND Arg1:T1 Arg2:T5	
R6	Has_temporal Arg1:T1 Arg2:T7	
T8	Measurement 154 168	Blood pressure
T9	Temporal 175 187	at screening
T10	Temporal 175 177;192 205	at randomization
T11	Value 209 219	= 180 mmHg
T12	Value 233 243	= 110 mmHg
T13	Measurement 248 253	siDBP
T14	Measurement 224 229	siSBP
R7	Has_value Arg1:T14 Arg2:T11	
R8	Has_value Arg1:T13 Arg2:T12	
*	OR T14 T13
T15	Scope 209 253	= 180 mmHg for siSBP or = 110 mmHg for siDBP
R9	Has_scope Arg1:T8 Arg2:T15	
R10	Has_temporal Arg1:T8 Arg2:T10	
R11	Has_temporal Arg1:T8 Arg2:T9	
T16	Condition 281 293	hypertension
T17	Qualifier 271 280	secondary
R12	Has_qualifier Arg1:T16 Arg2:T17	
T18	Mood 297 306	suspected
T19	Qualifier 310 319	secondary
T20	Condition 320 332	hypertension
R13	Has_qualifier Arg1:T20 Arg2:T19	
R14	Has_mood Arg1:T20 Arg2:T18	
T21	Condition 340 360	renovascular disease
T22	Condition 362 379;393 406	adrenal medullary hyperfunction
T23	Condition 384 406	cortical hyperfunction
T24	Condition 408 432	coarctation of the aorta
T25	Condition 434 452	hyperaldosteronism
T26	Qualifier 454 464	unilateral
T27	Qualifier 468 477	bilateral
*	OR T27 T26
T28	Condition 478 499	renal artery stenosis
T29	Scope 454 477	unilateral or bilateral
R15	Has_scope Arg1:T28 Arg2:T29	
T30	Condition 501 519	Cushing's syndrome
T31	Condition 521 537	pheochromocytoma
T32	Condition 539 564	polycystic kidney disease
*	OR T22 T23 T32 T31 T30 T28 T25 T24 T21
T33	Scope 340 564	renovascular disease, adrenal medullary and cortical hyperfunction, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease
*	OR T16 T20
T34	Scope 271 332	secondary hypertension or suspected of secondary hypertension
R16	Subsumes Arg1:T34 Arg2:T33	
T35	Condition 599 623	orthostatic hypertension
T36	Qualifier 587 598	symptomatic
R17	Has_qualifier Arg1:T35 Arg2:T36	
T37	Measurement 629 662	difference in the blood pressures
T38	Qualifier 671 732	measured at supine position and measured at standing position
T39	Value 736 745	= 20 mmHg
T40	Value 760 769	= 10 mmHg
T41	Measurement 774 779	siDBP
T42	Measurement 750 755	siSBP
R18	Has_value Arg1:T42 Arg2:T39	
R19	Has_value Arg1:T41 Arg2:T40	
R20	Has_qualifier Arg1:T37 Arg2:T38	
R21	AND Arg1:T37 Arg2:T42	
R22	AND Arg1:T37 Arg2:T41	
T43	Scope 629 779	difference in the blood pressures between measured at supine position and measured at standing position is = 20 mmHg for siSBP and = 10 mmHg for siDBP
T44	Scope 587 623	symptomatic orthostatic hypertension
R23	Subsumes Arg1:T44 Arg2:T43	
T45	Condition 795 824	type 1 diabetes mellitus (DM)
T46	Qualifier 828 840	uncontrolled
T47	Condition 841 843	DM
R24	Has_qualifier Arg1:T47 Arg2:T46	
*	OR T47 T45
T48	Procedure 857 872	insulin therapy
T49	Measurement 881 886	HbA1c
T50	Value 887 891	> 9%
R25	Has_value Arg1:T49 Arg2:T50	
*	OR T48 T49
T51	Scope 857 891	insulin therapy or with HbA1c > 9%
T52	Scope 795 843	type 1 diabetes mellitus (DM) or uncontrolled DM
R26	Subsumes Arg1:T52 Arg2:T51	
T53	Qualifier 908 914	severe
T54	Condition 915 933	cardiac conditions
R27	Has_qualifier Arg1:T54 Arg2:T53	
T55	Condition 935 948	heart failure
T56	Measurement 950 954	NYHA
T57	Value 955 967	Class 3 or 4
R28	Has_value Arg1:T56 Arg2:T57	
T58	Observation 970 977	history
T59	Condition 981 1005	ischemic cardiac disease
R29	Has_temporal Arg1:T59 Arg2:T58	
T60	Condition 1007 1022	unstable angina
T61	Condition 1024 1045	myocardial infarction
T62	Condition 1048 1076	peripheral vascular diseases
T63	Procedure 1078 1115	percutaneous transluminal angioplasty
T64	Procedure 1119 1147	coronary artery bypass graft
T65	Temporal 1148 1170	within recent 6 months
*	OR T64 T63
T66	Scope 1078 1147	percutaneous transluminal angioplasty or coronary artery bypass graft
R30	Has_temporal Arg1:T66 Arg2:T65	
*	OR T66 T62 T60 T61
T67	Scope 1007 1170	unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months
R31	Subsumes Arg1:T59 Arg2:T66	
R32	AND Arg1:T55 Arg2:T56	
*	OR T55 T59
T68	Scope 935 1170	heart failure (NYHA Class 3 or 4), history of ischemic cardiac disease (unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months
R33	Subsumes Arg1:T54 Arg2:T68	
T69	Qualifier 1187 1209	clinically significant
T70	Condition 1210 1233	ventricular tachycardia
T71	Condition 1235 1254	atrial fibrillation
T72	Condition 1256 1270	atrial flutter
T73	Qualifier 1280 1302	clinically significant
T74	Condition 1303 1313	arrhythmia
R34	Has_qualifier Arg1:T74 Arg2:T73	
*	OR T71 T70 T72
T75	Scope 1210 1270	ventricular tachycardia, atrial fibrillation, atrial flutter
R35	Has_qualifier Arg1:T75 Arg2:T69	
*	OR T75 T74
T76	Condition 1367 1404	hypertrophic occlusive myocardiopathy
T77	Qualifier 1406 1412	severe
T78	Condition 1413 1446	occlusive coronary artery disease
R36	Has_qualifier Arg1:T78 Arg2:T77	
T79	Condition 1448 1463	aortic stenosis
T80	Qualifier 1465 1492	hemodynamically significant
T85	Condition 1509 1530	mitral valve stenosis
T87	Condition 1543 1560	cardiogenic shock
T88	Observation 1532 1539	History
T82	Qualifier 1574 1580	severe
T81	Condition 1493 1505;1522 1530	aortic valve stenosis
*	OR T81 T85
T83	Scope 1493 1530	aortic valve or mitral valve stenosis
R37	Has_qualifier Arg1:T83 Arg2:T80	
*	OR T76 T78 T79 T83
R38	Has_temporal Arg1:T87 Arg2:T88	
T84	Condition 1581 1606	cerebrovascular disorders
R39	Has_qualifier Arg1:T84 Arg2:T82	
T86	Condition 1621 1627	stroke
T89	Condition 1629 1648	cerebral infarction
T90	Condition 1652 1671	cerebral hemorrhage
T91	Temporal 1672 1694	within recent 6 months
*	OR T86 T89 T90
T92	Scope 1621 1671	stroke, cerebral infarction or cerebral hemorrhage
R40	Has_temporal Arg1:T92 Arg2:T91	
T93	Scope 1574 1606	severe cerebrovascular disorders
R41	Subsumes Arg1:T93 Arg2:T92	
T94	Observation 1697 1704	History
T95	Temporal 1708 1715	current
T96	Observation 1728 1735	wasting
T97	Condition 1737 1747;1833 1841	autoimmune diseases
T98	Condition 1757 1777	rheumatoid arthritis
T99	Condition 1782 1810	systemic lupus erythematosus
*	OR T98 T99
T100	Condition 1815 1841	connective tissue diseases
T102	Scope 1757 1810	rheumatoid arthritis and systemic lupus erythematosus
R42	Subsumes Arg1:T97 Arg2:T102	
*	OR T97 T100 T96
*	OR T95 T94
T101	Scope 1697 1715	History or current
T103	Scope 1728 1841	wasting, autoimmune (such as rheumatoid arthritis and systemic lupus erythematosus) or connective tissue diseases
R43	Subsumes Arg1:T103 Arg2:T101	
T104	Qualifier 1874 1883	malignant
T105	Qualifier 1862 1870	moderate
T106	Condition 1884 1895	retinopathy
T107	Condition 1907 1925	retinal hemorrhage
T108	Condition 1927 1945	visual disturbance
T109	Condition 1950 1971	retinal microaneurysm
T110	Temporal 1972 1987	within 6 months
*	OR T108 T109 T107
*	OR T104 T105
T111	Scope 1862 1883	moderate or malignant
R44	Has_scope Arg1:T106 Arg2:T111	
T112	Scope 1907 1971	retinal hemorrhage, visual disturbance and retinal microaneurysm
R45	Has_temporal Arg1:T112 Arg2:T110	
R46	Subsumes Arg1:T106 Arg2:T112	
T113	Condition 2024 2043	intestinal diseases
T114	Qualifier 2004 2012	surgical
T115	Qualifier 2016 2023	medical
*	OR T114 T115
T116	Scope 2004 2023	surgical or medical
R47	Has_scope Arg1:T113 Arg2:T116	
T117	Procedure 2063 2072	surgeries
T118	Qualifier 2078 2127	could interfere with drug absorption distribution
T119	Qualifier 2078 2103;2129 2139	could interfere with drug metabolism
T120	Qualifier 2078 2103;2144 2155	could interfere with drug elimination
*	OR T119 T120 T118
T121	Scope 2078 2155	could interfere with drug absorption distribution, metabolism and elimination
*	OR T113 T117
T122	Scope 2004 2072	surgical or medical intestinal diseases or having received surgeries
R48	Has_scope Arg1:T122 Arg2:T121	
T123	Condition 2168 2178	malignancy
T124	Observation 2157 2167	History of
R49	Has_temporal Arg1:T123 Arg2:T124	
T125	Condition 2189 2197	leukemia
T126	Condition 2202 2210	lymphoma
T127	Temporal 2211 2232	within recent 5 years
T128	Condition 2244 2286	localized basal cell carcinoma of the skin
T129	Negation 2233 2243	except for
R50	Has_negation Arg1:T128 Arg2:T129	
*	OR T125 T126
T130	Scope 2189 2210	leukemia and lymphoma
R51	Subsumes Arg1:T123 Arg2:T130	
R52	AND Arg1:T123 Arg2:T128	
R53	Has_temporal Arg1:T123 Arg2:T127	
T131	Condition 2307 2328	inflammatory diseases
T132	Qualifier 2339 2346	chronic
T133	Procedure 2347 2372	anti-inflammatory therapy
T134	Drug 2347 2372	anti-inflammatory therapy
R54	multi Arg1:T133 Arg2:T134	
R55	Has_qualifier Arg1:T133 Arg2:T132	
R56	AND Arg1:T131 Arg2:T133	
T135	Condition 2374 2387	Renal failure
T136	Procedure 2391 2399	dialysis
R57	AND Arg1:T135 Arg2:T136	
T137	Measurement 2401 2404	AST
T138	Measurement 2408 2411	ALT
*	OR T137 T138
T139	Value 2412 2444	>2 x upper limit of normal (ULN)
T140	Scope 2401 2411	AST or ALT
R58	Has_value Arg1:T140 Arg2:T139	
T141	Measurement 2446 2462	Serum creatinine
T142	Value 2463 2474	> 1.5 x ULN
R59	Has_value Arg1:T141 Arg2:T142	
T143	Measurement 2476 2491	Serum potassium
T144	Value 2492 2504	< 3.5 mmol/L
T145	Value 2508 2519	>5.5 mmol/L
*	OR T144 T145
T146	Scope 2492 2519	< 3.5 mmol/L or >5.5 mmol/L
R60	Has_scope Arg1:T143 Arg2:T146	
T147	Temporal 2531 2548;2617 2633	co-administration during the study
T148	Qualifier 2552 2561	non-study
T149	Drug 2562 2585	antihypertensive agents
T150	Drug 2589 2616	contraindicated medications
*	OR T149 T150
R61	Has_qualifier Arg1:T149 Arg2:T148	
R62	Has_temporal Arg1:T149 Arg2:T147	
R63	Has_temporal Arg1:T150 Arg2:T147	
T151	Condition 2646 2662	hypersensitivity
T152	Drug 2666 2670	ARBs
T153	Drug 2674 2690	dihydropyridines
*	OR T152 T153
T154	Scope 2666 2690	ARBs or dihydropyridines
R64	Has_scope Arg1:T151 Arg2:T154	
T155	Condition 2703 2713	angioedema
T156	Procedure 2717 2726	treatment
T157	Drug 2732 2746	ACE inhibitors
T158	Drug 2750 2754	ARBs
*	OR T157 T158
T159	Scope 2732 2754	ACE inhibitors or ARBs
R65	Has_scope Arg1:T156 Arg2:T159	
R66	AND Arg1:T155 Arg2:T156	
T160	Observation 2692 2702	History of
R67	Has_temporal Arg1:T155 Arg2:T160	
T161	Observation 2635 2645	History of
R68	Has_temporal Arg1:T151 Arg2:T161	
T162	Condition 2756 2764	Pregnant
T163	Condition 2768 2777	lactating
T164	Person 2778 2783	women
T165	Person 2788 2794	female
T166	Observation 2809 2831	childbearing potential
*	OR T163 T162
*	OR T164 T165
T167	Scope 2756 2831	Pregnant or lactating women and female volunteers of childbearing potential
T168	Negation 2886 2889	not
T169	Mood 2890 2900	willing to
T170	Procedure 2908 2940	adequate method of contraception
R69	Has_negation Arg1:T169 Arg2:T168	
R70	Has_mood Arg1:T170 Arg2:T169	
T171	Pregnancy_considerations 2941 3546	(oral contraceptives, intrauterine device, condom, etc.) during the study. Women of childbearing potential who are not surgically sterile will be allowed to participate in the study only if they have negative pregnancy test at Visit 1 (screening) and should continue to use medically acceptable method of contraception (basic body temperature method and rhythm method will not be allowed). Women with no menses for = 12 months will be considered as postmenopausal state and method of contraception using hormonal contraception such as oral contraceptive should be initiated from or prior to the screening.
R71	AND Arg1:T167 Arg2:T170	
T172	Observation 3548 3555	History
T173	Condition 3559 3563;3575 3580	drug abuse
T174	Condition 3567 3580	alcohol abuse
T175	Temporal 3581 3601	within recent 1 year
*	OR T173 T174
T176	Scope 3559 3580	drug or alcohol abuse
R72	Has_temporal Arg1:T176 Arg2:T175	
R73	Has_temporal Arg1:T176 Arg2:T172	
T177	Drug 3632 3661	other investigational product
T178	Temporal 3662 3684	within recent 12 weeks
R74	Has_temporal Arg1:T177 Arg2:T178	
T179	Non-representable 3686 3782	Conditions which render a subject ineligible for the study at the discretion of the investigator
